Molecular biology of Philadelphia-negative myeloproliferative neoplasms
Rev. bras. hematol. hemoter
; Rev. bras. hematol. hemoter;34(2): 150-155, 2012.
Article
en En
| LILACS
| ID: lil-624771
Biblioteca responsable:
BR408.1
ABSTRACT
Myeloproliferative neoplasms are clonal diseases of hematopoietic stem cells characterized by myeloid hyperplasia and increased risk of developing acute myeloid leukemia. Myeloproliferative neoplasms are caused, as any other malignancy, by genetic defects that culminate in the neoplastic phenotype. In the past six years, since the identification of JAK2V617F, we have experienced a substantial increase in our knowledge about the genetic mechanisms involved in the genesis of myeloproliferative neoplasms. Mutations described in several genes have revealed a considerable degree of molecular homogeneity between different subtypes of myeloproliferative neoplasms. At the same time, the molecular differences between each subtype have become clearer. While mutations in several genes, such as JAK2, myeloproliferative leukemia (MPL) and LNK have been validated in functional assays or animal models as causative mutations, the roles of other recurring mutations in the development of disease, such as TET2 and ASXL1 remain to be elucidated. In this review we will examine the most prevalent recurring gene mutations found in myeloproliferative neoplasms and their molecular consequences.
Palabras clave
Texto completo:
1
Índice:
LILACS
Asunto principal:
Policitemia Vera
/
Leucemia Mieloide Aguda
/
Quinasas Janus
/
Mielofibrosis Primaria
/
Trombocitemia Esencial
/
Trastornos Mieloproliferativos
Límite:
Humans
Idioma:
En
Revista:
Rev. bras. hematol. hemoter
Asunto de la revista:
HEMATOLOGIA
Año:
2012
Tipo del documento:
Article